Hess, Clemens Friedrich

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","183"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Guerleyen, Hakan"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Dudas, Jozsef"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Saile, Bernhard"],["dc.date.accessioned","2018-11-07T11:02:14Z"],["dc.date.available","2018-11-07T11:02:14Z"],["dc.date.issued","2007"],["dc.format.extent","49"],["dc.identifier.isi","000247071800131"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51329"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","13th Congress of the Deutschen-Gesellschaft-fur-Radioonkologie"],["dc.relation.eventlocation","Hannover, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Radiation-induced reduced expression of Hsp27 in in vitro liver macrophages leads to apoptosis and release of TNF-alpha"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Pradier, Olivier"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Lederer, K."],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Schmidberger, Heinz"],["dc.date.accessioned","2018-11-07T10:45:26Z"],["dc.date.available","2018-11-07T10:45:26Z"],["dc.date.issued","2004"],["dc.format.extent","S351"],["dc.identifier.isi","000226237701326"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47500"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.publisher.place","Clare"],["dc.relation.conference","23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23)"],["dc.relation.eventlocation","Amsterdam, NETHERLANDS"],["dc.relation.issn","0167-8140"],["dc.title","A phase I study of fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S479"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.lastpage","S480"],["dc.bibliographiccitation.volume","81"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Guerleyen, Hakan"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Thello, K."],["dc.contributor.author","Dudas, Jozsef"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Saile, Bernhard"],["dc.date.accessioned","2018-11-07T09:13:58Z"],["dc.date.available","2018-11-07T09:13:58Z"],["dc.date.issued","2006"],["dc.identifier.isi","000242719101490"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27292"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Ireland Ltd"],["dc.publisher.place","Clare"],["dc.relation.conference","Conference of the Spanish-Portuguese-and -Latin-American-Association"],["dc.relation.eventlocation","Leipzig, GERMANY"],["dc.relation.issn","0167-8140"],["dc.title","Irradiation leads to sensitization of hepatocytes to TNF-alpha- mediated apoptosis by upregulation of IKB expression"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","185"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Wagner, D."],["dc.contributor.author","Steenken, K."],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Hess, C. F."],["dc.date.accessioned","2018-11-07T08:29:41Z"],["dc.date.available","2018-11-07T08:29:41Z"],["dc.date.issued","2009"],["dc.format.extent","96"],["dc.identifier.isi","000268225500239"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16711"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","15th Annual Conference of the Deutschen-Gesellschaft-fur-Radioonkologie"],["dc.relation.eventlocation","Bremen, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Simultaneous integrated boost irradiation in breast cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T08:55:29Z"],["dc.date.available","2018-11-07T08:55:29Z"],["dc.date.issued","2011"],["dc.format.extent","49"],["dc.identifier.isi","000291236200133"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22914"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","TGFB1 Pro25 allele as a risk marker for higher-grade acute Organ toxicity (CTC >= Grad2) during neoadjuvant Chemoradiotherapy in patients with locally advanced Rectal cancer (UICC Stage II/III)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","119"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","International Journal of Radiation Biology"],["dc.bibliographiccitation.lastpage","128"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Pradier, Olivier"],["dc.contributor.author","Damm, C."],["dc.contributor.author","Dorr, W."],["dc.contributor.author","Jackel, M. C."],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Schmidberger, Heinz"],["dc.date.accessioned","2018-11-07T10:41:20Z"],["dc.date.available","2018-11-07T10:41:20Z"],["dc.date.issued","2003"],["dc.description.abstract","Purpose: The effect of recombinant human keratinocyte growth factor (rHuKGF) on the proliferation, clonogenic capacity and colony size of low-passage human epithelial tumour cells was tested in vitro. Materials and methods: Five tumour cell cultures derived from head and neck squamous cell carcinomas, three cultures derived from pleural effusions of carcinomas of different origin and normal human nasal epithelial cells were analysed in passages 2-4. Expression of FGF7 and its receptor (FGFR2) were determined by the RNase protection assay. Cells were incubated with rHuKGF (10-200 ng ml(-1)) 3 days before or immediately after plating for clonal growth in serum-depleted media. To determine cellular radiosensitivity, single doses of 1-8 Gy X-rays were applied. Colony formation as well as colony size, reflecting the number of cell divisions, was determined after 10-15 days of growth in rHuKGF-treated and control cells. Results: Normal nasal epithelial cells showed a two- to threefold increase in the number of cell divisions due to rHuKGF-treatment. In tumour cell cultures, significant stimulation of proliferation occurred in only one of eight samples. Tumour cells expressed FGF7 mRNA and protein, and low levels of FGFR2 mRNA. The addition of rHuKGF to the medium of the tumour cell cultures influenced neither radiation-induced impairment of proliferation nor clonogenic cell survival. Conclusion: rHuKGF has been shown to ameliorate the radiation tolerance of normal epithelia. The minimum in vitro tumour cell response to rHuKGF compared with normal epithelial cells suggests a potential for selective protection of normal epithelia during radiotherapy. The low FGFR2 expression as well as the FGF7 expression in the tumour cells may contribute to their resistance to rHuKGF treatment."],["dc.identifier.doi","10.1080/0955300021000045682"],["dc.identifier.isi","000180776800005"],["dc.identifier.pmid","12569015"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46510"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0955-3002"],["dc.title","Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","81"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cancer/Radiothérapie"],["dc.bibliographiccitation.lastpage","88"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Herrmann, M. K. A."],["dc.contributor.author","Bloch, E."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Koerber, Wolfgang"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Mueller, M."],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T08:57:24Z"],["dc.date.available","2018-11-07T08:57:24Z"],["dc.date.issued","2011"],["dc.description.abstract","Introduction. - Curative therapy for patients with small-cell lung cancer (SCLC) is based on multidrug chemotherapy combinations and radiotherapy. After a long time follow-up, the aim of the study was to evaluate the efficacy and toxicity of sequential chemo-radiotherapy and the effect of prophylactic cranial irradiation (PCI). Methods. - From 1995-2005, 96 patients with SCLC (64 limited-disease [LD], 32 extensive-disease [ED]: median age 61 years [range 39-79]) were treated at our department with varying chemotherapy regimens and sequential mediastinal radiotherapy (50 Gy + 10 Gy boost in case of residual disease after chemotherapy). Afterwards, 15 patients with LD, good general condition and at least partial response after local treatment received PCI (30 Gy). Results. - After a median follow-up of 78.6 months, 20 patients remained alive (20.8%, median survival time 18.2 months). The 2-/5-year overall survival rates were 33.8% and 12.6%, the 2-/5-year loco-regional control rates were 30.3% and 24.5%, respectively. Distant metastases occurred in 43 patients (24 cerebral). Cerebral metastasis occurred in 6.7% and 27.2% of the patients with PCI and without PCI respectively. Only tumor stage showed a statistically significant impact on overall survival and loco-regional control in multivariate analysis. Radiotherapy was well tolerated. Grade 3/4 toxicity occurred in seven patients. Prognosis of patients with SCLC remains poor. Administration of PCI in selected patients bears a decrease in the incidence of cerebral metastases. Alternative chemotherapy schemes as well as irradiation schemes and techniques should be the substance of future randomized trials. (C) 2010 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved."],["dc.identifier.doi","10.1016/j.canrad.2010.03.017"],["dc.identifier.isi","000289580700001"],["dc.identifier.pmid","20708424"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23393"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier"],["dc.relation.issn","1278-3218"],["dc.title","Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC - treatment results after long-term follow-up and literature overview"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","181"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Martin, A."],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Pradier, Olivier"],["dc.date.accessioned","2018-11-07T11:06:37Z"],["dc.date.available","2018-11-07T11:06:37Z"],["dc.date.issued","2005"],["dc.format.extent","24"],["dc.identifier.isi","000229590600085"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52360"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","11th Annual Congress of the German-Society-for-Radiooncology"],["dc.relation.eventlocation","Karlsruhe, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Mitomycin-C duration infusion in primary radiochemotherapy of advanced inoperable head and neck tumours - Results of a Phase I study"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","190"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Helms, C."],["dc.contributor.author","Frank, M. A."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T09:38:37Z"],["dc.date.available","2018-11-07T09:38:37Z"],["dc.date.issued","2014"],["dc.format.extent","90"],["dc.identifier.isi","000337052500218"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33101"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","20th Annual Congress of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","Cytokinesis-block micronucleus cytome assay for in vivo and in vitro lymphocyte radiosensitivity in patients undergoing radiochemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","817"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Cancer/Radiothérapie"],["dc.bibliographiccitation.lastpage","821"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Nitsche, M."],["dc.contributor.author","Horstmann, Olaf"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Pradier, Olivier"],["dc.contributor.author","Schmidberger, Heinz"],["dc.date.accessioned","2018-11-07T11:08:24Z"],["dc.date.available","2018-11-07T11:08:24Z"],["dc.date.issued","2008"],["dc.description.abstract","Background. - Recent Studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-alpha (IFN-alpha) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods. - Eleven patients with histological diagnosis of localized carcinoma of the pancreas (n = 7) or periampullary (n =4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three T4 carcinomas. Fifty-five per cent (6/11) of the patients presented with positive lymph node involvement. One histological Grade I, six Grade II and three Grade III were detected. External conformal irradiation to a total dose of 50.4 Gy with 1.8 Gy per day was delivered. All patients received a concomitant chemotherapy with continuous 5-FU 200 mg/m(2) per day on 28 treatment days and intravenous bolus cisplatin 30 mg/m(2) per week (Day 2, 9, 16, 23, 30). A recombinant r-IFN-alpha was administered on three days weekly during Week one to five of the radiotherapy course as subcutanous injections with 3 3 Mio. I.U. weekly. Results. - The four-year overall Survival rate for all patients was 55%. In the neoadjuvant group, three of four patients died due to progressive disease; in the adjuvant group, combined chemoradioimmunotherapy lead to controlled disease in five of seven patients. The overall toxicity was well-managed. Conclusion. - Our data strengthens the hypothesis of concomitant chemoradioimmunotherapy with 5-FU, IFN-alpha and cisplatin as a possible new treatment of pancreatic cancer in resected patients. (C) 2008 Elsevier Masson SAS. All rights reserved."],["dc.identifier.doi","10.1016/j.canrad.2008.09.009"],["dc.identifier.isi","000262218600009"],["dc.identifier.pmid","18996727"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52769"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier"],["dc.relation.issn","1278-3218"],["dc.title","Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: Results of a feasibility study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]